The Funding of Biopharmaceutical Research and Development. Woodhead Publishing Series in Biomedicine
- Language: English
- 284 Pages
- Published: October 2013
The 2014 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production.
The survey includes responses from 238 responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations from 30 countries. The survey methodology includes input from an additional 158 direct suppliers of raw materials, services, and equipment to this industry.
CHAPTER 0: Demographics
CHAPTER 1: Introduction and Discussion
CHAPTER 2: Overview of Critical Issues in Bioprocessing
CHAPTER 3: Emerging Issues in Biopharmaceutical Manufacturing
CHAPTER 4: Capacity Utilization
CHAPTER 5: Current and Future Capacity Constraints
CHAPTER 6: Future Capacity Expansions
CHAPTER 7: Outsourcing Trends in Biopharmaceutical Manufacturing
CHAPTER 8: Disposables and Single-Use Systems in Biopharmaceutical Manufacturing
CHAPTER 9: Downstream Purification
CHAPTER 10: Quality Issues, Batch Failures, and PAT in Biopharmaceutical Manufacturing
CHAPTER 11: Hiring, Employment Growth, and Training in Biopharmaceutical
CHAPTER 12: Suppliers to Biopharmaceutical Manufacturing and Life Sciences
The 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production from BioPlan Associates, Inc., a global analysis of 238 biomanufacturers and 178 suppliers in 31 countries. The 514 page study is the industry's definitive, quantitative analysis and includes 11 years of biopharma trends and opportunities, including in-depth analysis of specific issues affecting the industry. This analysis covers the events shaping the past year, and evaluates what will shape the industry over the next five years. The study covers 12 critical areas, including: industry growth, downstream processing, single use systems, outsourcing, capacity, and quality management and much more!
This new report features trends including mAbs, biosimilars, outsourcing, disposables that are opening opportunities and challenges to the entire industry. The study also compares over time how Western Europe, the U.S., and Rest of the World biomanufacturers differ in demands for new technologies. Innovation has never been better funded and broad in scope.
Global capacity data show the impact of biosimilars, outsourcing, regulatory, as well as downstream processing and single-use devices, and how they are creating growth potential in both capacity and in the number of facilities coming on-line. Capacity utilization remains overall constant across mammalian and microbial systems, according to this year's respondents.
This will affect:
- Overall industry growth
- Opportunities for suppliers to the industry
- Demand for skilled staff and better technology
- Regulatory demands on the industry